Navigation Links
An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety
Date:12/17/2010

NEW YORK, Dec. 17, 2010 /PRNewswire-FirstCall/ -- A study published this week by ITG (NYSE: ITG) revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.  Over 60% of neurologists in ITG's study cited safety concerns and monitoring as limiting their use of the drug, but most indicated that their prescribing of Gilenya will increase significantly over the course of 2011 as they continue to shift inadequate responders from other MS therapies to the new drug.  Early switching data from ITG's proprietary panel of neurologists indicates that BIIB's Avonex may be the biggest loser of all, as nearly one-third of switches to Gilenya thus far have been from Avonex.

The study titled Event Pulse: Launch of Gilenya shows that Gilenya has been detailed heavily to neurologists since its launch.  Neurologists in the study reported more frequent details on Gilenya in November than any of the other MS therapies.  Study findings reveal that Novartis reps seem to be promoting the drug's unique oral formulation and its efficacy compared to market leaders, especially Biogen Idec's Avonex. Still, results from the study show that Novartis has not been able to completely allay neurologists' concerns about Gilenya's safety. Until resolved, Gilenya will likely be prescribed primarily for patients who have discontinued or have had an inadequate response to other MS therapie
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
10. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
11. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5sqnn3/global_rising ) ... Stars Outlook 2015" report to their offering. ... sought after with fresh vigor as new targets , ... poised to bring a paradigm change in the way ... Stem cell therapy/Regenerative Medicine space. The number ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. ... multi-disciplinary clinical specialty, aimed at improving patient care ... individually adjust the dose of drugs for improving ...
(Date:3/5/2015)... March 5, 2015  MGC Diagnostics Corporation (NASDAQ: ... company, today reported financial results for the first ... 2015 first quarter domestic equipment, supplies and accessories ... $3.7 million in the 2014 first quarter.  During ... or $338,000 in revenue, compared to 14 accounts, ...
Breaking Medicine Technology:Global Pharma Rising Stars Outlook 2015 2Global Therapeutic Drug Monitoring Report 2015 - Technologies, Markets, and Companies Analysis 2014-2024 2MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 2MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 3MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 4MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 5MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 6MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 7MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 8MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 9MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 10MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 11MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 12
... (Nasdaq: ATHX ), a clinical stage ... Retail Investor Conferences.com presentation is available for on-demand ... Executive Officer of Athersys, presented to retail investors ... To view the archived presentation, click on ...
... Corporation, a privately held, clinical stage biopharmaceutical company developing ... today announced the appointment of Dr. Dennis Fenton, long-time ... Fenton,s appointment expands the Genelux Corporation board to 5 ... build one of the world,s most successful pharmaceutical companies ...
Cached Medicine Technology:Athersys, Inc. - Retail Investor Conferences.com Presentation Now Available Online 2Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive 2
(Date:3/5/2015)... 05, 2015 Supply & Demand Chain ... of “Pros to Know” in the supply chain industry, ... of MEBC’s leadership team were included on this year’s ... received this award due to their hard work, their ... for meeting and resolving client needs and challenges. ...
(Date:3/5/2015)... New York, NY (PRWEB) March 05, 2015 ... NY orthopedic Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named ... in the New York Metro area. Dr. Glashow has ... in its authoritative guide to the top specialty care ... 2015. , The prestigious Castle Connolly program, which carefully ...
(Date:3/5/2015)... March 05, 2015 As a ... (AAPA) review of Clearstream, LLC ’s products, ... Clearstream’s MediDefense line of products—led by their mPulse ... Affinity Partner Program. , The AAPA—which represents a ... all medical and surgical specialties in the U.S.—advocates ...
(Date:3/5/2015)... Diego, CA (PRWEB) March 05, 2015 ... it is now running on 100% pollution-free electricity ... Arcadia Power. , As an Arcadia Power ... Protection Agency’s (EPA) Green Power Partnership requirements, joining ... Starbucks that also purchase clean energy. Earth Source ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... 2007) -- A University of South Florida fetal surgeon ... rare but potentially devastating condition in which placental blood ... labor, leaving the baby without vital blood and oxygen. ... frequently deadly for newborns. , The case was ...
... delaying surgical treatment remains the standard of care for ... in the December issue of the Journal of the ... belief, early cholecystectomy -- or surgical removal of the ... mild to moderate gallstone pancreatitis with no increase in ...
... Inc. (Nasdaq:,CYBX) announced that effective December 18, 2007, ... Endo-Surgery granting exclusive rights to,the company,s patents and ... the treatment of obesity and two related,co-morbidities, diabetes ... has agreed to pay Cyberonics a signing fee ...
... 18 DuPont has selected,its Cooper River plant ... announced to significantly expand production of high-performance,DuPont(TM) Kevlar(R) ... The investment at the Cooper River site, which ... Berkeley County, will include construction of,a new Kevlar(R) ...
... WALTHAM, Mass., Dec. 18 Art Mellor is one ... million worldwide suffering from,Multiple Sclerosis (MS). It,s, a debilitating ... other,symptoms. So it,s no wonder that Mellor, the founder ... interested in snow and more,interested in raising the funds ...
... 17, 2007) -- The Leon Levy Foundation has ... Hospital/Weill Cornell Medical Center in New York City ... neurological disorders: chemotherapy-related cognitive dysfunction in adult cancer ... as "water on the brain," a progressive neurologic ...
Cached Medicine News:Health News:Fetal surgeon shows for first time that laser procedure may treat vasa previa 2Health News:Fetal surgeon shows for first time that laser procedure may treat vasa previa 3Health News:Early surgical treatment contributes to better outcomes in gallstone pancreatitis cases 2Health News:Cyberonics Licenses Obesity-Related Patents 2Health News:Cyberonics Licenses Obesity-Related Patents 3Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 2Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 3Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 4Health News:DuPont Selects South Carolina Site for Planned $500 Million Investment to Expand Production of High-Performance Kevlar(R) Fiber 5Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 3Health News:$1.4 million grant awarded to study 2 little-understood neurological disorders 2
... unique lateral fiber possessing a ... rotated to any one of ... fibers in one. The fiber ... and coagulation and back to ...
... the first truly lateral, all quartz fiber. ... (NA) compression technology for Total Internal Reflection ... The resulting output is virtually indistinguishable from ... transmission efficiency in a round spot of ...
Stirrups provide a safe system for positioning patients in a variety of lithotomy positions. Power-assisted positioning, as well as abduction, assures proper positioning of the patient. Includes one ...
Use to prevent arm or leg drops during surgical procedures. The dimensions are 10"W x 6"H. These come in pairs. Optional Gel pad available (BD2245)...
Medicine Products: